ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 678

Quantifying Change In Pulmonary Function As a Prognostic Marker In Systemic Sclerosis-Related Interstitial Lung Disease

Owen Moore1,2, Susanna Proudman3, Nicole Goh4, Tamera Corte5, Hannah Rouse6, Oliver Hennessy6, Vivek Thakkar7, Joanne Sahhar8, Janet E. Roddy9, Peter Youssef10, Eli Gabbay11, Peter Nash12, Jane Zochling13, Wendy Stevens14 and Mandana Nikpour15, 1Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, 2Rheumatology, Derriford Hospital, Plymouth, United Kingdom, 3Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, 4Department of Respiratory Medicine, Alfred Hospital, Melbourne, Australia, 5Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia, 6Department of Radiology, St. Vincent’s Hospital, Melbourne, Australia, 7St Vincent's Hospital, Melbourne, Australia, 8Rheumatology Unit, Monash Medical Centre, Clayton, Australia, 9Royal Perth Hospital, Perth, Australia, 10Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Australia, 11Advanced Lung Disease Unit, Royal Perth Hospital, Perth, Australia, 12Rheumatology Research Unit, Nambour Hospital, Sunshine Coast, Australia, 13Menzies Research Institute Tasmania, Hobart, Australia, 14Rheumatology, St Vincent's Hospital, Melbourne, Australia, 15Department of Medicine (St Vincent's Hospital), University of Melbourne, Fitzroy, Australia

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Lung Disease and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in systemic sclerosis (SSc) but it is not severe or progressive in all patients. Serial pulmonary function tests (PFTs) can predict outcomes but there are no established data regarding what is a clinically meaningful decline in these variables in SSc-ILD. We sought to quantify change in pulmonary function as a predictor of outcome in SSc-ILD.

Methods: Patients with SSc with ILD defined by high resolution CT lung scan were identified through a nationwide cohort study. All PFTs performed during follow-up, including forced expiratory volume in one second (FEV1) (L), forced vital capacity (FVC) (L), FEV1/FVC ratio (%), diffusing capacity of the lung for carbon monoxide (DLCO) (ml/min/mmHg) and  DLCO by alveolar volume ratio (DLCO/VA) (ml/min/mmHg/L) were retrieved. Demographic and disease-related data were prospectively collected. The rate of change over four years in the absolute value for each variable was calculated for each patient using a regression line of best fit. Percentage change in absolute values over the first year of follow-up from diagnosis of SSc-ILD (±90 days) was determined.  The composite outcome variable was deterioration, defined as need for home oxygen or lung transplantation, or death.  Univariable Cox regression models were used to determine the relationship between each of rate of decline and percentage decline in each PFT variable and outcome.  Receiver operating characteristics (ROC) curves were used to determine the best cut-off points to predict adverse outcomes.

Results: Among 264 patients in whom PFT data were available from time of ILD diagnosis, there were 49 events (38 deaths, 10 prescribed supplemental oxygen, one lung transplant) over a mean (±SD) follow-up of 3.0 (±1.7) years. The rates of decline over time in each of FVC, DLCO & DLCO/VA were significantly predictive of deterioration or death (hazard ratios [HR] of 0.06, 0.637 and 0.06 respectively, p values all <0.0001). Cut-off values of zero (i.e. no overall change in PFTs over four years) gave the optimal sensitivity-specificity trade-off with negative predictive values (NPVs) of 88-96%. The percentage changes in FVC, DLCO and DLCO/VA over one year from diagnosis (±90 days) were significantly associated with outcome (HRs 1.06 [p<0.04], 1.07  [p<0.0001] and 1.05 [p<0.04] respectively). The best trade-off between sensitivity and specificity was a decline in FVC of 10% and in DLCO and DLCO/VA of 15% with NPVs of 92-93%. A decline in DLCO/VA of 15% predicted a poor outcome with a likelihood ratio of 7.62.

Conclusion: The course that SSc-ILD takes is evident within the first 1-4 years following its diagnosis. Patients who have no decline in PFTs over the first 4 years do well. As seen in idiopathic pulmonary fibrosis, a decline within the first year in FVC of 10% or more and DLCO or DLCO/VA of 15% or more bodes badly and identifies patients who should be monitored more closely and considered for therapy.


Disclosure:

O. Moore,
None;

S. Proudman,
None;

N. Goh,
None;

T. Corte,
None;

H. Rouse,
None;

O. Hennessy,
None;

V. Thakkar,
None;

J. Sahhar,
None;

J. E. Roddy,
None;

P. Youssef,
None;

E. Gabbay,
None;

P. Nash,
None;

J. Zochling,
None;

W. Stevens,
None;

M. Nikpour,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quantifying-change-in-pulmonary-function-as-a-prognostic-marker-in-systemic-sclerosis-related-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology